移行上皮癌(尿路上皮癌)(Transitional Cell Carcinoma (Urothelial Cell Carcinoma)):治療薬開発パイプライン動向(2014年下半期版)

◆英語タイトル:Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline Review, H2 2014
◆商品コード:GMDHC5821IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2014年12月10日
◆ページ数:57
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥208,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥416,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥624,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、世界における移行上皮癌(尿路上皮癌)(Transitional Cell Carcinoma (Urothelial Cell Carcinoma))の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。

・イントロダクション
・移行上皮癌(尿路上皮癌)(Transitional Cell Carcinoma (Urothelial Cell Carcinoma))の概要
・移行上皮癌(尿路上皮癌)(Transitional Cell Carcinoma (Urothelial Cell Carcinoma))治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・移行上皮癌(尿路上皮癌)(Transitional Cell Carcinoma (Urothelial Cell Carcinoma))パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・製品
・大学/研究機関別、研究中の製品
・移行上皮癌(尿路上皮癌)(Transitional Cell Carcinoma (Urothelial Cell Carcinoma))治療薬開発に取り組んでいる企業:企業別製品パイプライン
・移行上皮癌(尿路上皮癌)(Transitional Cell Carcinoma (Urothelial Cell Carcinoma))治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Transitional Cell Carcinoma (Urothelial Cell Carcinoma) – Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Transitional Cell Carcinoma (Urothelial Cell Carcinoma) – Pipeline Review, H2 2014’, provides an overview of the Transitional Cell Carcinoma (Urothelial Cell Carcinoma)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Transitional Cell Carcinoma (Urothelial Cell Carcinoma)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Transitional Cell Carcinoma (Urothelial Cell Carcinoma) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Transitional Cell Carcinoma (Urothelial Cell Carcinoma) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Transitional Cell Carcinoma (Urothelial Cell Carcinoma) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) Overview 6
Therapeutics Development 7
Pipeline Products for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) – Overview 7
Pipeline Products for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) – Comparative Analysis 8
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) – Therapeutics under Development by Companies 9
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) – Pipeline Products Glance 10
Clinical Stage Products 10
Early Stage Products 11
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) – Products under Development by Companies 12
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) – Companies Involved in Therapeutics Development 13
Altor BioScience Corporation 13
AstraZeneca PLC 14
Boston Biomedical, Inc. 15
Daiichi Sankyo Company, Limited 16
Dendreon Corporation 17
Mirati Therapeutics Inc. 18
Novartis AG 19
Sanofi 20
Teva Pharmaceutical Industries Limited 21
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) – Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Target 23
Assessment by Mechanism of Action 25
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 31
ALT-801 – Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
AZD-4547 – Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
BBI-503 – Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
cabazitaxel – Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
CEP-11981 – Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
dovitinib lactate – Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
lapuleucel-t – Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
mocetinostat – Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
tigatuzumab – Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) – Recent Pipeline Updates 49
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) – Dormant Projects 54
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) – Discontinued Products 55
Appendix 56
Methodology 56
Coverage 56
Secondary Research 56
Primary Research 56
Expert Panel Validation 56
Contact Us 57
Disclaimer 57

[List of Tables]
Number of Products under Development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma), H2 2014 7
Number of Products under Development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Clinical Stage Development, H2 2014 10
Comparative Analysis by Early Stage Development, H2 2014 11
Products under Development by Companies, H2 2014 12
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by Altor BioScience Corporation, H2 2014 13
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by AstraZeneca PLC, H2 2014 14
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by Boston Biomedical, Inc., H2 2014 15
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by Daiichi Sankyo Company, Limited, H2 2014 16
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by Dendreon Corporation, H2 2014 17
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by Mirati Therapeutics Inc., H2 2014 18
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by Novartis AG, H2 2014 19
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by Sanofi, H2 2014 20
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by Teva Pharmaceutical Industries Limited, H2 2014 21
Assessment by Monotherapy Products, H2 2014 22
Number of Products by Stage and Target, H2 2014 24
Number of Products by Stage and Mechanism of Action, H2 2014 26
Number of Products by Stage and Route of Administration, H2 2014 28
Number of Products by Stage and Molecule Type, H2 2014 30
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) Therapeutics - Recent Pipeline Updates, H2 2014 49
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Dormant Projects, H2 2014 54
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Discontinued Products, H2 2014 55

[List of Figures]
Number of Products under Development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma), H2 2014 7
Number of Products under Development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Clinical Stage Development, H2 2014 10
Assessment by Monotherapy Products, H2 2014 22
Number of Products by Top 10 Targets, H2 2014 23
Number of Products by Stage and Top 10 Targets, H2 2014 23
Number of Products by Top 10 Mechanism of Actions, H2 2014 25
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 25
Number of Products by Top 10 Routes of Administration, H2 2014 27
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 28
Number of Products by Top 10 Molecule Types, H2 2014 29
Number of Products by Stage and Top 10 Molecule Types, H2 2014 30

【掲載企業】

Altor BioScience Corporation
AstraZeneca PLC
Boston Biomedical, Inc.
Daiichi Sankyo Company, Limited
Dendreon Corporation
Mirati Therapeutics Inc.
Novartis AG
Sanofi
Teva Pharmaceutical Industries Limited

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[移行上皮癌(尿路上皮癌)(Transitional Cell Carcinoma (Urothelial Cell Carcinoma)):治療薬開発パイプライン動向(2014年下半期版)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆